PR Newswire: news distribution, targeting and monitoring
2014
See more news releases in Banking & Financial Services  | Legal Issues  | Legal Issues

Attention Unilife Corporation Investors: Unilife Corporation Misled Investors According to a Newly Filed Class Action

Share with Twitter Share with LinkedIn

SAN DIEGO, Calif. and YORK, Pa., Nov. 6, 2013 /PRNewswire/ -- Shareholder rights law firm Robbins Arroyo LLP announces that an investor of Unilife Corporation (NASDAQ: UNIS) ("Unilife") has filed a federal securities fraud class action complaint in the U.S. District Court for the Middle District of Pennsylvania.  The complaint alleges that the company and certain of its officers violated the Securities and Exchange Act of 1934 between July 13, 2011 and September 9, 2013 (the "Class Period").    

(Logo: http://photos.prnewswire.com/prnh/20130103/MM36754LOGO)

Unilife Accused of Misleading Investors Regarding the Company's Compliance with FDA Regulations

Shares of Unilife fell $0.52 per share, or more than 14%, on September 4, 2013, after publication of a Forbes article discussing Unilife's fiscal year loss of $63.2 million on revenue of just $2.7 million. The report also disclosed that customer demand for Unilife's products was such that the company's primary manufacturing facility was operating at 3% of capacity, or approximately 2 million syringes per year. Then, on September 9, 2013, Forbes published an article detailing allegations in a lawsuit filed by a former Unilife employee concerning various regulatory violations at the company and the suppression of internal reports detailing Unilife's inability to produce the company's syringes below cost.

According to the complaint, defendants made false and/or misleading statements and failed to disclose that: (i) the company's Unifill syringes failed to comply with the U.S. Food and Drug Administration's ("FDA") validation processes; (ii) the company's Quality Management System failed to comply with FDA's regulations; and (iii) Unilife intentionally increased purchases of Unifill component parts to create the appearance that it was producing at increased volumes despite low customer demand and lack of capacity to support those purchases.

Unilife Shareholders Are Encouraged to Contact Shareholder Rights Law Firm Robbins Arroyo

If you invested in Unilife and would like to discuss your shareholder rights, please contact attorney Darnell R. Donahue at (800) 350-6003, DDonahue@robbinsarroyo.com, or via the information form on the firm's shareholder rights blog: http://www.robbinsarroyo.com/shareholders-rights-blog/unilife-corporation/.

Robbins Arroyo LLP is a nationally recognized leader in securities litigation and shareholder rights law.  The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits, and has helped its clients realize more than $1 billion of value for themselves and the companies in which they have invested. 

Attorney Advertising. Past results do not guarantee a similar outcome.  

Contact:
Darnell R. Donahue
Robbins Arroyo LLP
DDonahue@robbinsarroyo.com
(619) 525-3990 or Toll Free (800) 350-6003
www.robbinsarroyo.com

SOURCE Robbins Arroyo LLP



RELATED LINKS
http://robbinsumeda.com

Featured Video

Journalists and Bloggers

Visit PR Newswire for Journalists for releases, photos, ProfNet experts, and customized feeds just for Media.

View and download archived video content distributed by MultiVu on The Digital Center.

Share with Twitter Share with LinkedIn
 

Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

 
 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

 
 

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.

 

Online Member Center

Not a Member?
Click Here to Join
Login
Search News Releases
Advanced Search
Search
  1. PR Newswire Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
  5. Send a News Release